Abstract:Chao Cao, 1– 4 Lin Zhang, 2, 3 Fuli Liu, 2, 3 Jie Shen 1– 4 1 Research Center for Chemical Injury, Emergency and Critical Medicine of Fudan University, Shanghai, People's Republic of China; 2 Key Laboratory of Chemical Injury, Emergency and Critical Medicine of Shanghai Municipal Health Commission, Shanghai, People's Republic of China; 3 Center of Emergency and Critical Medicine in Jinshan Hospital of Fudan University, Shanghai, People's Republic of China; 4 Shanghai Medical College Fudan University, Shanghai, People's Republic of China Correspondence: Jie Shen, Research Center for Chemical Injury, Emergency and Critical Medicine of Fudan University, Shanghai, 201508, People's Republic of China, Tel +86 02134189990, Email Acute respiratory distress syndrome (ARDS) presents as a form of acute respiratory failure resulting from non-cardiogenic pulmonary edema due to excessive alveolocapillary permeability, which may be pulmonary or systemic in origin. In the last 3 years, the coronavirus disease 2019 pandemic has resulted in an increase in ARDS cases and highlighted the challenges associated with this syndrome, as well as the unacceptably high mortality rates and lack of effective treatments. Currently, clinical treatment remains primarily supportive, including mechanical ventilation and drug-based therapy. Mesenchymal stem cell (MSC) therapies are emerging as a promising intervention in patients with ARDS and have promising therapeutic effects and safety. The therapeutic mechanisms include modifying the immune response and assisting with tissue repair. This review provides an overview of the general properties of MSCs and outlines their role in mitigating lung injury and promoting tissue repair in ARDS. Finally, we summarize the current challenges in the study of translational MSC research and identify avenues by which the discipline may progress in the coming years. Keywords: acute respiratory distress syndrome, mesenchymal stromal cells, therapeutic effect, potential mechanisms Acute respiratory distress syndrome (ARDS) remains a very common cause of respiratory failure and requires intensive medical care. It is a common disease observed clinically and is characterized by acute and refractory hypoxia noncardiogenic pulmonary edema, diffuse alveolar-capillary membrane damage, and reduced compliance. 1 The most common clinicopathological manifestations associated with ARDS development include pneumonia and sepsis. 1 The diagnostic criteria for ARDS have changed since its first description in 1967, 2 and its current definition is characterized by the acute onset of impaired oxygenation (ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen [PaO 2 /FiO 2 ] <300 mmHg) and bilateral infiltrates on chest imaging in the absence of left atrial hypertension as the dominant cause of pulmonary edema. 3 Based on the Berlin definition proposed in 2012, ARDS is classified into three categories of severity according to the level of hypoxemia: mild (PaO 2 /FiO 2 , 201–300 mmHg), moderate (PaO 2 /FiO 2 , 100–≤200 mmHg), and severe (PaO 2 /FiO 2 , <100 mmHg). 3 The main clinical manifestations include low oxygenation, low lung compliance, and hyperphysiological dead space caused by damage to the alveolar epithelium and vascular endothelial cells, as well as increased pulmonary vascular permeability. 4 ARDS remains a relatively frequent and lethal or disabling syndrome in clinical practice. An observational study of patients in 496 intensive care units (ICUs) from 50 different countries reported that clinical recognition rates ranged from 10% of ICU patients to 23% of mechanically ventilated patients according to the criteria for ARDS. 5 However, mortality rates remain sobering: >30% in-hospital, 5 with moderate to severe ARDS reaching a rate of 43% in-hospital mortality at 90 days. 6 Even if they recover, survivors remain burdened by functional limitations resulting from muscle weakness or cognitive impairment. 7 Despite five decades of advances in basic and clinical research having passed, there is still no effective goal-directed pharmacotherapy, and therapies remain primarily supportive, including lung protective ventilation and conservative fluid management strategies. 8–10 ARDS is particularly relevant as a consequence of the global coronavirus disease 2019 (COVID-19), affecting hundreds of millions of people worldwide in the last 3 years. There have been abundant developments in the understanding of the pathogenesis of ARDS over the past 50 years, yielding valuable insights into the mechanisms r -Abstract Truncated-

Bibliometric Analysis of MSC-based Therapies for Non-COVID-19 ARDS

The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials

Treatment of Acute Respiratory Distress Syndrome with Allogeneic Adipose-Derived Mesenchymal Stem Cells: a Randomized, Placebo-Controlled Pilot Study.

Clinical Study Using Mesenchymal Stem Cells for the Treatment of Patients with Severe COVID-19

Mesenchymal Stem Cell-Based Treatments for COVID-19: Status and Future Perspectives for Clinical Applications

Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment

Current Landscape of Mesenchymal Stem Cell Therapy in COVID Induced Acute Respiratory Distress Syndrome

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome

Rationale for the Clinical Use of Adipose-Derived Mesenchymal Stem Cells for COVID-19 Patients.

A Bibliometric Analysis of Mesenchymal Stem Cell-Derived Exosomes in Acute Lung Injury/Acute Respiratory Distress Syndrome from 2013 to 2022

Recent progress in mesenchymal stem cell-based therapy for acute lung injury

Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS

Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives

Multipotent mesenchymal stromal/stem cell-based therapies for acute respiratory distress syndrome: current progress, challenges, and future frontiers

Mesenchymal Stem Cells As a Potential Treatment for Critically Ill Patients with Coronavirus Disease 2019

Intravenous Administration of Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSC) for Acute Respiratory Distress Syndrome Due to COVID-19 Infection

Research Status of the Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of COVID-19-Related Pneumonia: A Systematic Review and Meta-Analysis

Therapeutic Benefits of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome: Potential Mechanisms and Challenges

Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review

Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment.

Strategies to Enhance Mesenchymal Stem Cell-Based Therapies for Acute Respiratory Distress Syndrome